Aemetis (NASDAQ:AMTX) Share Price Passes Below 200-Day Moving Average – Here’s Why

Aemetis, Inc. (NASDAQ:AMTX) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.52 and traded as low as $1.29. Aemetis shares last traded at $1.38, with a volume of 978,680 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AMTX shares. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Aemetis in a report on Friday, March 14th. Ascendiant Capital Markets boosted their price target on shares of Aemetis from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, March 17th. Finally, StockNews.com raised Aemetis to a “sell” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $14.56.

Aemetis Trading Up 2.2 %

The company has a market capitalization of $73.58 million, a P/E ratio of -0.61 and a beta of 1.30. The stock’s fifty day moving average is $1.74 and its 200 day moving average is $2.52.

Institutional Trading of Aemetis

A number of institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Aemetis by 16.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company’s stock valued at $103,000 after purchasing an additional 5,281 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Aemetis by 128.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company’s stock valued at $28,000 after acquiring an additional 5,859 shares in the last quarter. Barclays PLC lifted its stake in Aemetis by 14.7% in the fourth quarter. Barclays PLC now owns 54,492 shares of the specialty chemicals company’s stock worth $146,000 after acquiring an additional 6,996 shares during the period. Wells Fargo & Company MN boosted its holdings in Aemetis by 20.0% in the fourth quarter. Wells Fargo & Company MN now owns 45,741 shares of the specialty chemicals company’s stock valued at $123,000 after acquiring an additional 7,622 shares in the last quarter. Finally, FMR LLC increased its position in Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares during the period. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.